SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, reported record second-quarter revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period last year. The company's first-half revenue reached $25.0 million, up 65.6% from $15.1 million in the first half of 2025. These results underscore the continued momentum for its SSi Mantra surgical robotic system, which is gaining traction in global markets.
The company's SSi Mantra installations rose 30.4% to 30 systems during the quarter, bringing the installed base to 224 systems across 12 countries. Cumulative surgeries performed with the system reached 12,272, demonstrating growing clinical adoption. The increase in installations is a key driver of revenue growth, as the company generates recurring revenue from service contracts and consumables associated with each system.
Gross profit for the second quarter increased 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% in the year-earlier quarter. For the first half, gross profit rose 77.5% to $12.4 million, with an improved gross margin compared to the prior year. The margin dip in Q2 may reflect higher costs related to expansion and investments in regulatory processes.
Looking ahead, regulatory milestones could serve as important catalysts for SS Innovations. The company is targeting FDA clearance for the SSi Mantra by the first quarter of 2027 and EU CE marking by the end of 2026. Achieving these approvals would open access to the U.S. and European markets, potentially accelerating adoption and revenue growth. The company's telesurgery achievements are also extending the clinical profile of the platform, showcasing its capabilities in remote surgery and expanding its appeal to healthcare providers.
The financial results were released via NewMediaWire, and further information is available in the company's newsroom at https://ibn.fm/SSII. As with any forward-looking statements, investors should consider the risks outlined in the company's SEC filings, as detailed in the disclaimer on the InvestorBrandNetwork website.
